1. Home
  2. VCIG vs PHIO Comparison

VCIG vs PHIO Comparison

Compare VCIG & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VCI Global Limited

VCIG

VCI Global Limited

HOLD

Current Price

$1.48

Market Cap

12.5M

ML Signal

HOLD

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$1.25

Market Cap

14.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VCIG
PHIO
Founded
2013
2003
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
14.6M
IPO Year
2022
2011

Fundamental Metrics

Financial Performance
Metric
VCIG
PHIO
Price
$1.48
$1.25
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$10.67
AVG Volume (30 Days)
828.2K
362.9K
Earning Date
05-08-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.81
52 Week High
$23.40
$4.19

Technical Indicators

Market Signals
Indicator
VCIG
PHIO
Relative Strength Index (RSI) 43.32 54.11
Support Level $0.75 $1.11
Resistance Level $2.18 $1.43
Average True Range (ATR) 0.27 0.08
MACD -0.22 0.00
Stochastic Oscillator 3.65 52.27

Price Performance

Historical Comparison
VCIG
PHIO

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: